Literature DB >> 19028756

Increase in percent free prostate-specific antigen in men with chronic kidney disease.

Laila Bruun1, Caroline Savage, Angel M Cronin, Jonas Hugosson, Hans Lilja, Anders Christensson.   

Abstract

BACKGROUND: Prostate-specific antigen (PSA) occurs in different molecular forms in serum: free PSA (fPSA) and complexed PSA (cPSA), the sum of which corresponds to total PSA (tPSA). In addition to tPSA, percent fPSA is widely used in the detection of prostate cancer. Free PSA, approximately 28 kDa, is eliminated by glomerular filtration. Previous data showed that men with end-stage renal dysfunction requiring chronic dialysis have increased percent fPSA. In this study, we evaluated whether moderate-to-severe chronic renal dysfunction, but with no need for dialysis, also importantly affects percent fPSA.
METHODS: The study group consisted of 101 men (median age 57 years, interquartile range 46-68) with chronic kidney disease and no diagnosis of prostate cancer. Their median glomerular filtration rate (GFR) was 23 mL/min/1.73 m(2) (interquartile range 16-33; range 8-83), determined by iohexol clearance. Controls included 5264 men (median age 57 years, interquartile range 54-62) attending a prostate cancer screening program with no diagnosis of prostate cancer during 8 years of follow-up.
RESULTS: With adjustment for age, median fPSA levels and percent fPSA were significantly higher (P < 0.001) in patients with renal dysfunction, 0.45 microg/L and 47.2%, respectively, compared to controls, 0.29 microg/L and 29.9%, respectively. Regression analysis in the study group showed a significant association between GFR and percent fPSA (P = 0.036).
CONCLUSIONS: The percent fPSA is importantly influenced by moderately impaired renal function in men with chronic kidney disease. For such men, use of the current clinical decision limits for percent fPSA could cause some men with prostate cancer to be misdiagnosed as having benign disease, and therefore fPSA should not be used to diagnose prostate cancer in these patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19028756      PMCID: PMC2721427          DOI: 10.1093/ndt/gfn632

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  27 in total

1.  cPSA and fPSA elimination in African-American men.

Authors:  B J Martin; C Cheli; R Davis; M Ward; M Kokatnur; D Mercante; D Lifsey; W Rayford
Journal:  Prostate Cancer Prostatic Dis       Date:  2003       Impact factor: 5.554

2.  A simple method for the determination of glomerular filtration rate.

Authors:  J Bröchner-Mortensen
Journal:  Scand J Clin Lab Invest       Date:  1972-11       Impact factor: 1.713

3.  Significance and metabolism of complexed and noncomplexed prostate specific antigen forms, and human glandular kallikrein 2 in clinically localized prostate cancer before and after radical prostatectomy.

Authors:  H Lilja; A Haese; T Björk; M G Friedrich; T Piironen; K Pettersson; E Huland; H Huland
Journal:  J Urol       Date:  1999-12       Impact factor: 7.450

4.  Percent-free prostate specific antigen is elevated in men on haemodialysis or peritoneal dialysis treatment.

Authors:  Laila Bruun; Thomas Björk; Hans Lilja; Charlotte Becker; Ove Gustafsson; Anders Christensson
Journal:  Nephrol Dial Transplant       Date:  2003-03       Impact factor: 5.992

5.  Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors.

Authors:  A Christensson; C B Laurell; H Lilja
Journal:  Eur J Biochem       Date:  1990-12-27

6.  A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer.

Authors:  U H Stenman; J Leinonen; H Alfthan; S Rannikko; K Tuhkanen; O Alfthan
Journal:  Cancer Res       Date:  1991-01-01       Impact factor: 12.701

7.  Plasma clearance of a new contrast agent, iohexol: a method for the assessment of glomerular filtration rate.

Authors:  E Krutzén; S E Bäck; I Nilsson-Ehle; P Nilsson-Ehle
Journal:  J Lab Clin Med       Date:  1984-12

8.  Rapid elimination by glomerular filtration of free prostate specific antigen and human kallikrein 2 after renal transplantation.

Authors:  Laila Bruun; Henrik Ekberg; Thomas Bjørk; Hans Lilja; Peter Høglund; Anders Christensson
Journal:  J Urol       Date:  2004-04       Impact factor: 7.450

9.  Shift of the f/t-PSA quotient in relation to renal insufficiency: consequences for the early detection of prostate carcinoma in patients with terminal renal failure.

Authors:  Kersten Fischer; Amir Hamza; Andreas Wicht; Hagen Loertzer; Paolo Fornara
Journal:  Anticancer Res       Date:  2007 Jul-Aug       Impact factor: 2.480

10.  Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma.

Authors:  Jonas Hugosson; Gunnar Aus; Hans Lilja; Pär Lodding; Carl-Gustav Pihl
Journal:  Cancer       Date:  2004-04-01       Impact factor: 6.860

View more
  9 in total

1.  Prostate Cancer Screening and Management in Solid Organ Transplant Candidates and Recipients.

Authors:  Ezequiel Becher; Alex Wang; Herbert Lepor
Journal:  Rev Urol       Date:  2019

2.  Editorial comment. Association between glomerular filtration rate, free, total, and percent free prostate-specific antigen.

Authors:  Anders Christensson; Hans Lilja
Journal:  Urology       Date:  2010-11       Impact factor: 2.649

3.  Intra-individual short-term variability of prostate-specific antigen and other kallikrein markers in a serial collection of blood from men under evaluation for prostate cancer.

Authors:  Anders Christensson; Laila Bruun; Thomas Björk; Angel M Cronin; Andrew J Vickers; Caroline J Savage; Hans Lilja
Journal:  BJU Int       Date:  2010-10-18       Impact factor: 5.588

4.  Association between percent-free prostate-specific antigen and glomerular filtration rate in transrectal ultrasound-guided biopsy-proven patients with prostate-specific antigen levels ranging from 4 to 10 ng/ml.

Authors:  Jae Heon Kim; Ji Sung Shim; Jae Hyun Bae; Hong Seok Park; Du Geon Moon; Soon-Sun Kwon; Jae Young Park
Journal:  World J Urol       Date:  2013-01-03       Impact factor: 4.226

5.  The relation of serum parathyroid hormone and serum calcium to serum levels of prostate-specific antigen: a population-based study.

Authors:  Halcyon G Skinner; Gary G Schwartz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-10-27       Impact factor: 4.254

6.  Albuminuria, Kidney Function, and Cancer Risk in the Community.

Authors:  Yejin Mok; Shoshana H Ballew; Yingying Sang; Josef Coresh; Corinne E Joshu; Elizabeth A Platz; Kunihiro Matsushita
Journal:  Am J Epidemiol       Date:  2020-09-01       Impact factor: 4.897

7.  Do the values of prostate specific antigen obtained from fresh and dried urine reflect the serum measurements?

Authors:  Hasan S Sağlam; Osman Köse; Fatma Ozdemir; Oztuğ Adsan
Journal:  Urol Ann       Date:  2013-04

Review 8.  Tumour markers and kidney function: a systematic review.

Authors:  Giuseppe Coppolino; Davide Bolignano; Laura Rivoli; Giuseppe Mazza; Piera Presta; Giorgio Fuiano
Journal:  Biomed Res Int       Date:  2014-02-06       Impact factor: 3.411

9.  Cancer risk among elderly persons with end-stage renal disease: a population-based case-control study.

Authors:  Fatma M Shebl; Joan L Warren; Paul W Eggers; Eric A Engels
Journal:  BMC Nephrol       Date:  2012-07-26       Impact factor: 2.388

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.